DBV Technologies

#FoodAllergy management is a journey that evolves throughout childhood. At DBV, we aim to advance solutions that meet families where they are on their journey. ​ Our investigational #PeanutAllergy patch is designed to engage the immune system and build sustained tolerance that lasts over time. ​Over 1.1 million patches have been administered to more than 1,600 children ages 1 to 7 across our clinical programs. Driven by a commitment to developing a treatment for food allergy, we continue to push progress forward with ongoing research across multiple age groups.​ Learn more about our current pediatric #PeanutAllergy safety study in toddlers aged 1-3 here: bit.ly/478WmNA

At DBV, our culture is grounded in our Four Cs, the values that shape how we work and why we do what we do to advance #FoodAllergy research for children and families. In this employee spotlight, find out which “C” resonates the most with Jennifer Meunier, our Internal Communications Project Manager, and what it means at DBV. If our values speak to you, we invite you to explore opportunities to join our team and help move our mission forward: bit.ly/3Hk9uF0 #DBVTeam

We’re looking forward to connecting with leaders across the healthcare landscape next week: 1️⃣The Citizens Life Sciences Conference, where we will participate in a #FiresideChat on March 10. 2️⃣ The Leerink Partners Global Healthcare Conference, where members of our leadership team will host 1-on-1 meetings. We welcome these opportunities to connect with industry peers and the investor community to share insights on recent company progress as we continue advancing our investigational treatment option for pediatric #PeanutAllergy. To watch a live webcast of the Fireside Chat at Citizens, register here: bit.ly/4laeBqU The presentation will also be available on the Events section of our website. Learn more: bit.ly/4l9mNHG

Today, we presented at the 2026 @AAAAI_org Annual Meeting! Swipe through data highlights and expert insights and from our: 📍Oral Abstract Presentation, where David Fleischer, MD, shared additional positive results from the successful VITESSE Phase 3 study in peanut-allergic children aged 4-7 years, including clinically meaningful changes in reaction threshold. Read our full data release to learn more: bit.ly/402JnZ6 #AAAAI26

Allergic reactions are unpredictable; accidental exposures can still occur despite best efforts to avoid them. For many families, avoidance alone may not be enough. There remains a real need for proactive approaches that not only reduce the risk and severity of allergic reactions but also address the barriers to care that exists with current therapies. In this @ContempPEDS article, Dr. Fleischer, Global Principal Investigator of our VITESSE study in children 4-7 with #PeanutAllergy, highlights an important distinction: our investigational treatment delivers microgram amounts of peanut protein through intact skin, offering families a non-invasive approach to treatment without having to ingest the allergen. Learn more: bit.ly/4kXldJ6

This month, our teams across the U.S. and France came together to connect and reflect on our progress to strengthen the partnerships that help us move forward. These moments reinforce how collaboration drives our work to advance food allergy research and potential solutions for children and families. Behind every milestone is a global team united by purpose, innovation, and an unwavering commitment to the #FoodAllergy community.

We look forward to participating at the upcoming 2026 @AAAAI_org Annual Meeting, where we will share insights and results reflecting continued progress in our investigational treatment for children and toddlers with #PeanutAllergy. Find details on our oral abstract presentation, product theater, and company booth here: bit.ly/46A6ygT #AAAAI26

Valentine’s Day is just around the corner! While many parents, teachers and students look forward to sharing sweet treats on this fun holiday, classroom celebrations can create heightened risk for accidental allergen exposure. At DBV, we understand that this can bring added stress for families and children managing #FoodAllergies. Learn how we’re working to help reduce the risk and severity of accidental exposure reactions: bit.ly/3S6OALw

More children in the U.S. are living with #PeanutAllergy than ever before, and the increasing prevalence has driven a growing need for more accessible, safe and effective treatment options. The COMFORT Toddlers clinical trial, a supplemental safety study evaluating our investigational treatment option in toddlers aged 1-3 years with peanut allergy, is advancing research to address this critical gap in care. Our innovative technology based on epicutaneous immunotherapy is being developed as a non-invasive, potentially disease-modifying approach to desensitization. Uniquely designed with the needs of young children in mind, it aims to re-educate the immune system and protect from accidental exposure reactions. In our latest research spotlight, principal investigators from participating COMFORT Toddlers clinical trial sites highlight the ongoing work to offer a potential treatment option that could benefit families and allergists alike. To learn more about our ongoing trial, visit: comfort-toddlers-study.com/learnmore/

During our recent investor call, our CEO, Daniel Tassé, shared why the positive topline results from VITESSE, our Phase 3 study in peanut-allergic children aged 4–7 years, represent a pivotal moment in our work to advance #PeanutAllergy care. The discussion focused on how these results pave a clear regulatory pathway to FDA submission in 1H26 for our investigational, non-invasive treatment designed specifically with children and families in mind. Watch the replay here to learn more: bit.ly/4a2nmPD

We’re pleased to announce €166.7 million in gross proceeds following the full exercise of the ABSA warrants and BS warrants issued on our March 2025 financing.​ With this capital, we are sufficiently funded to support operations and commercial preparedness to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved.​ Learn more: bit.ly/49LgpBq

We’re proud to be recognized among @SnackSafely’s Ten Food Allergy Research Breakthroughs of 2025, underscoring the significance of recent positive topline results from our Phase 3 VITESSE trial in peanut-allergic children ages 4-7. Learn more👉 bit.ly/49EmUWG

We’ll be in San Francisco during #JPM2026, attending the LifeSci Partners Corporate Access Event from January 12-14. Members of our leadership team will share insights on recent company progress, including positive topline results from our Phase 3 VITESSE trial in peanut-allergic children aged 4-7 years, and discuss what’s ahead for DBV in 2026. We look forward to connecting with global industry leaders and the healthcare investment community. Get in touch to learn more and subscribe to stay up to date on DBV news:🔗 bit.ly/49CtCMJ

Happy Holidays from the DBV team! 2025 has been a year of meaningful milestones and scientific progress. As we look ahead to 2026, we’re energized by momentum, gratitude, and a continued commitment to advancing safe and innovative potential treatment options for the #FoodAllergy community. Thank you to our employees, partners, and the families we serve for your support and trust. Here’s to continuing the journey together.

Check out the highlights from our Phase 3 VITESSE trial of VIASKIN® Peanut patch, with recent positive topline results in peanut-allergic children aged 4-7 years. This robust clinical evidence from the largest immunotherapy trial ever conducted in this patient population paves a clear pathway to BLA submission in 1H26, and underscores the potential for a new treatment option for the nearly 400,000 children living with peanut allergy, if approved. Learn more: bit.ly/48HSinZ

We’re thrilled to share positive topline data from the VITESSE Phase 3 study of VIASKIN® Peanut patch in peanut allergic children aged 4–7. With this important milestone, our planned BLA submission is on track for the first half of 2026. We extend our gratitude to the participating families, investigators, and their teams for their commitment and partnership as we work to advance this potential, non-invasive treatment. Join our conference call today at 5pm ET and read the release to learn more: bit.ly/48HSinZ

For families living with #FoodAllergies, even simple daily activities require thoughtful planning and constant vigilance, from reading every food label to preparing for the risk of accidental exposure. At DBV Technologies, we’re committed to offering families a safe, effective, and accessible treatment option to help protect them from accidental exposure reactions. Our work is driven by the realities families face every day and the need for innovative approaches in food allergy management.​ Learn more: bit.ly/4fWxxFk

At DBV, we’re proud to spotlight the culture that drives our commitment to making a difference for families living with #FoodAllergies and other immunological diseases. In our latest spotlight, Robert Pietrusko, Chief Regulatory Officer, reflects on what working toward a potential treatment option for food allergies means to him. The shared purpose and dedication of our team is what propels us forward and inspires how we show up every day. To learn more, check out our careers page and explore current job openings here: bit.ly/3Hk9uF0 #TeamDBV

#ICYMI, catch up on recent headlines featuring end-of-study data on the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers, and our planned Phase 2 study in infants with #PeanutAllergy. Pieces by @HealthDay, @Allergic Living, and @GoHealio cover insights on the study results presented at @ACAAI 2025 and what the findings may mean for the future of pediatric #FoodAllergy care. Stay in the know with more like this from DBV and subscribe for the latest updates, news, and scientific progress: bit.ly/495uSZD

Happy Thanksgiving from the DBV Technologies team! As families gather this season, we’re reminded of the importance of inclusion and awareness for those living with food allergies. At DBV, we remain committed to advancing early intervention and supporting the food allergy community year-round. Learn how to make your holiday safer and more inclusive: bit.ly/43WLy2K